Clinical Trials Sponsored by Venn Biosciences Corporation

Total 50 results

Venn Biosciences Corporation

Completed

Non-invasive Identification of Colorectal Cancer and Adenomas in Early Stages (NICE)

Colorectal Cancer

United States
Venn Biosciences Corporation

Completed

Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)

Ovarian Cancer | Adnexal Mass | Pelvic Mass

Philippines, United States, Malaysia, Australia
Qure Healthcare, LLC
Venn Biosciences Corporation

Withdrawn

Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test

Non Small Cell Lung Cancer
Graviton Bioscience Corporation

Completed

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

Phase 1

United States
Alliancells Bioscience Corporation Limited

Unknown

Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis (LC)

Liver Cirrhosis

China
Incyte BioSciences France

Completed

Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

Chronic Myeloid Leukemia

France
Incyte Biosciences Benelux

Completed

Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

Chronic Myeloid Leukemia | CML | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Ph+ ALL

Belgium
Alliancells Bioscience Corporation Limited

Unknown

Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

China
Assembly Biosciences
Arbutus Biopharma Corporation

Terminated

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Chronic Hepatitis B

Australia, Canada, Bulgaria, New Zealand
Incyte Biosciences UK

Completed

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United Kingdom, Ireland
Incyte Biosciences Japan GK

Not yet recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host-disease
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
Incyte Biosciences International Sàrl

Recruiting

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Lymphoma | Acute Myeloid Leukemia | Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Solid Tumors | Chronic Phase Chronic Myeloid Leukemia | Accelerated Phase Chronic Myeloid Leukemia | Blast Phase Chronic Myeloid Leukemia

Spain, Italy, France, Germany, United Kingdom, Belgium, Sweden, Denmark, Netherlands
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Incyte Biosciences Japan GK

Completed

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Japan
Incyte Biosciences International Sàrl

Completed

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States, Belgium, Australia, Spain
Incyte Biosciences International Sàrl

Completed

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Metastatic Cancer | Advanced Malignancies

United States, United Kingdom, Spain, Switzerland
Perle Bioscience, Inc.
Syreon Corporation

Withdrawn

The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients (IIT)

Type 1 Diabetes
Incyte Biosciences Japan GK

Completed

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Lymphoma

Japan
Incyte Biosciences Japan GK

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

Solid Tumors

Japan
Incyte Biosciences Japan GK

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707

Healthy Participants

Japan
Incyte Biosciences International Sàrl

Completed

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Metastatic Cancer | Advanced Malignancies

United States
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
Incyte Biosciences International Sàrl

Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Advanced Malignancies

United States
Incyte Biosciences International Sàrl

Terminated

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States, France, Italy, United Kingdom
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Incyte Biosciences International Sàrl

Withdrawn

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

BCR-ABL Positive Acute Lymphoblastic Leukemia

Germany, France, Czechia
Matthew Varacallo
Pacira Biosciences

Not yet recruiting

Impact of Opioid Avoidance Protocol for ACL Reconstruction

Post Operative Pain | ACL Tear

United States
University Medical Center Groningen
Akston Biosciences Corporation

Completed

Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study (ACT)

Covid19

Netherlands
Annick Desjardins
Ambit Biosciences Corporation

Completed

Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

Glioma

United States
Mayo Clinic
Ambit Biosciences Corporation; Kern Medical Center

Completed

Trial Comparing a Multi-Modal Pain Protocol With and Without Opioids Following Total Joint Arthroplasty

Total Knee Arthroplasty

United States
Therapeutic Advances in Childhood Leukemia Consortium
Ambit Biosciences Corporation

Completed

AC220 for Children With Relapsed/Refractory ALL or AML

Lymphoblastic Leukemia, Acute, Childhood | Myelogenous Leukemia, Acute, Childhood

United States
Ottawa Heart Institute Research Corporation
Spartan Bioscience Inc.

Completed

Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) (RAPID STEMI)

STEMI

Canada
Ottawa Heart Institute Research Corporation
Spartan Bioscience Inc.

Completed

ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (RAPID GENE)

Acute Coronary Syndrome | Percutaneous Coronary Intervention | Stable Coronary Artery Disease

Canada
Abramson Cancer Center at Penn Medicine
Incyte Corporation

Not yet recruiting

Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC) (HCC)

Hepatocellular Carcinoma

United States
Andrews Research & Education Foundation
EmCyte Corporation; BioSciences Research Associates, Inc

Completed

Bone Marrow Aspirate Compared to Platelet Rich Plasma for Treating Knee Osteoarthritis (EmCyte)

Knee Osteoarthritis

United States
FluidAI Medical
Hamilton Health Sciences Corporation; Ontario Bioscience Innovation Organization

Recruiting

Economic Evaluation of Stream™ Platform (CostAL)

Anastomotic Leak

Canada
Taiwan Carbon Nano Technology Corporation
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

Recruiting

Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge

Vaginitis | Vaginal Infection

Taiwan
NHS National Waiting Times Centre Board
Boston Scientific Corporation; Diagram B.V.; Venn Life Sciences; Cardialysis B.V.

Unknown

Xience Versus Synergy in Left Main PCI (IDEAL-LM)

Coronary Artery Disease
Alliancells-PuRui Biocience Co., Ltd.
Zhongyuan Union Stem Cell Bio-engineering Corporation

Unknown

Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection

Renal Cell Carcinoma | Hepatocellular Carcinoma | Lung Cancer

China
Cedars-Sinai Medical Center
National Cancer Institute (NCI); VA Long Beach Healthcare System; Nonagen Bioscience...

Recruiting

A Diagnostic for the Early Detection of Bladder Cancer

Bladder Cancer

United States
University of Virginia
PBM C19 Research, LLC (a COVID-19 research entity of the Paul Manning Foundation) and other collaborators

Completed

Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients (SafeDrop)

COVID-19

United States
Cedars-Sinai Medical Center
National Cancer Institute (NCI); University of California, Los Angeles; University... and other collaborators

Recruiting

Predicting BCG Response

Bladder Cancer

United States, Japan
Cedars-Sinai Medical Center
National Cancer Institute (NCI); University of California, San Francisco; Fred... and other collaborators

Active, not recruiting

A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer

Bladder Cancer

United States, Japan
Cedars-Sinai Medical Center
National Cancer Institute (NCI); University of California, Los Angeles; Fred... and other collaborators

Recruiting

A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer

Bladder Cancer

United States, Japan
Cedars-Sinai Medical Center
National Cancer Institute (NCI); University of California, Los Angeles; University... and other collaborators

Recruiting

A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

Bladder Cancer

United States, Japan
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute and other collaborators

Active, not recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Prostate Cancer

United States

Clinical Trials Sponsored by Venn Biosciences Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations